Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
FORDEN v. ALLERGAN PLC et al
Case Number:
2:16-cv-09449
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Calcagni & Kanefsky
- Carella Byrne
- Cohn Lifland
- Faruqi & Faruqi
- Kantrowitz Goldhamer
- Kessler Topaz
- Lite DePalma
- Lowey Dannenberg
- Morgan Lewis
- Motley Rice
- Reed Smith
- Safirstein Law
- Schnader Harrison
- Seeger Weiss
- Spector Roseman
- Weiner Law Group LLP
Companies
Sectors & Industries:
-
November 23, 2021
Allergan Investors' Attys Claim $30.9M Of Price-Fixing Deal
The attorneys who secured a $130 million settlement for Allergan investors who sued the pharmaceutical company over allegations that it participated in a generic drug price-fixing scheme will walk away with nearly $31 million for their trouble, according to a new court filing.
-
July 12, 2021
Allergan Strikes $130M Deal Over Drug Price-Fixing Claims
Allergan has agreed to a $130 million settlement over class claims it took part in a generic-drug price-fixing scheme, investors said in seeking a New Jersey federal court's blessing for what they suggested is the first deal struck in a federal securities case related to such allegations.
-
January 06, 2021
Feds Want In On Allergan Collusion Suit Amid Criminal Probe
The government asked a New Jersey federal court Wednesday to let it step into investors' proposed class action against Allergan over claims the pharmaceutical titan took part in a generic-drug price-fixing scheme, citing the need to ensure the integrity of related criminal affairs.
-
August 06, 2019
Allergan Can't Escape Generic Drug Price-Fixing Suit
Allergan must face a proposed class action accusing the pharmaceutical company of taking part in a generic drug price-fixing scheme after a New Jersey federal judge rejected the company's dismissal bid Tuesday, finding its investors convincingly contended that Allergan violated federal antitrust and securities laws.